Trastuzumab - an overview

Trastuzumab deruxtecan trastuzumab The story of trastuzumab begins with Axel Ullrich's dedication to the concept that receptor tyrosine kinases must be the key to many human trastuzumab In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed

trastuzumab Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2 Trastuzumab uses multiple mechanisms to interfere with HER2 downstream